Palatin Technologies (PTN) Receives Media Sentiment Score of 0.30

News headlines about Palatin Technologies (NYSE:PTN) have trended positive recently, according to Alpha One. Alpha One, a service of Accern, rates the sentiment of press coverage by analyzing more than twenty million blog and news sources. Alpha One ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Palatin Technologies earned a daily sentiment score of 0.30 on Alpha One’s scale. Alpha One also assigned media stories about the biopharmaceutical company an impact score of 93 out of 100, indicating that recent press coverage is extremely likely to have an effect on the company’s share price in the near future.

These are some of the news articles that may have effected AlphaOne’s scoring:

Insider Buying and Selling by Quarter for Palatin Technologies (NYSE:PTN)

Palatin Technologies (NYSE:PTN) remained flat at $0.35 during mid-day trading on Friday. 1,418,945 shares of the company traded hands. The firm’s 50 day moving average is $0.40 and its 200 day moving average is $0.42. Palatin Technologies has a 12 month low of $0.29 and a 12 month high of $0.90. The stock’s market capitalization is $53.48 million.

Palatin Technologies (NYSE:PTN) last released its earnings results on Thursday, May 18th. The biopharmaceutical company reported ($0.02) earnings per share for the quarter, missing the consensus estimate of $0.10 by $0.12. The firm had revenue of $10.82 million for the quarter, compared to analyst estimates of $60 million. During the same quarter in the prior year, the business posted ($0.01) earnings per share. Analysts predict that Palatin Technologies will post ($0.06) EPS for the current fiscal year.

Separately, Canaccord Genuity reissued a “buy” rating and issued a $6.00 target price on shares of Palatin Technologies in a research note on Thursday, June 1st.

TRADEMARK VIOLATION WARNING: “Palatin Technologies (PTN) Receives Media Sentiment Score of 0.30” was originally posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of United States & international trademark and copyright legislation. The original version of this article can be viewed at

About Palatin Technologies

Palatin Technologies, Inc is a biopharmaceutical company. The Company is engaged in developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Its programs are based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems.

Receive News & Ratings for Palatin Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palatin Technologies Inc. and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply